drugset / Trial / NCT06219174
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to establish the safety, toxicity, and tolerability of Difluoromethylornithine (DFMO) in combination with pembrolizumab in advanced/metastatic Non-Small Cell Lung Cancer (NSCLC). Researchers also want to investigate how effective DFMO is at treating patients with advanced/ metastatic NSCLC.
Timeline
- Start
- 2024-08-07
- Primary completion
- 2029-08
- Completion
- 2029-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eflornithine | Small molecule | 4500 mg/m2 | Oral |
| Subject | Eflornithine | Small molecule | 6750 mg/m2 | Oral |
| Subject | Eflornithine | Small molecule | 9000 mg/m2 | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |